Group | Frequency (Hz) | Amplitude (pA) | 10-90% rise time (ms) | τ (ms) | Charge transfer (fC) | |
---|---|---|---|---|---|---|
Status epilepticus | Before NPY | 0.29 ± 0.07 | 12.4 ± 0.8 | 2.9 ± 0.3 | 24.5 ± 1.5 | 163 ± 12 |
Plus NPY | 0.24 ± 0.07* | 12.3 ± 1.0 | 3.2 ± 0.3 | 26.6 ± 2.5 | 183 ± 16 | |
Before BIIE0246 | 0.33 ± 0.08 | 11.6 ± 0.3 | 3.6 ± 0.3 | 22.0 ± 2.0 | 142 ± 10 | |
Plus BIIE0246 | 0.42 ± 0.09* | 11.3 ± 0.3 | 3.9 ± 0.2 | 21.7 ± 1.7 | 148 ± 11 | |
Control | Before NPY | 0.33 ± 0.14 | 10.6 ± 0.3 | 4.7 ± 0.6 | 27.0 ± 2.2 | 178 ± 9 |
Plus NPY | 0.34 ± 0.15 | 10.7 ± 0.3 | 4.5 ± 0.6 | 26.7 ± 1.9 | 181 ± 11 | |
Before BIIE0246 | 0.30 ± 0.08 | 11.1 ± 0.3 | 4.5 ± 0.4 | 28.1 ± 1.7 | 178 ± 13 | |
Plus BIIE0246 | 0.32 ± 0.07 | 11.1 ± 0.3 | 4.7 ± 0.3 | 29.7 ± 3.3 | 189 ± 21 |
The number of mEPSCs recorded during a 3 min period and the properties of averaged mEPSCs were determined before and during exposure to the test compound. Values are means ± SEM for eight granule cells per group. *p < 0.01 compared with values obtained just before exposure to the test compound (paired t test). All other comparisons between test compound and pretreatment values yielded p » 0.05.